{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:19:47Z","timestamp":1783448387851,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cabotegravir and rilpivirine long\u2010acting (CAB+RPV LA) is a novel switch strategy for people living with HIV. Our aim was to identify factors associated with therapeutic failure (TF) and virological failure (VF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single\u2010centre prospective cohort study. We reviewed all people living with HIV who initiated CAB+RPV LA between 14 February 2023 and 6 May 2025 in the hospital. Reasons for treatment discontinuation (VF, toxicity, poor adherence, death, pregnancy, transfer to another centre or oral bridging) were analysed, as well as virological effectiveness and the emergence of resistance mutations. Safety, adherence and overall regimen durability were also evaluated. The proportion of patients with HIV\u2010RNA\u2009&lt;\u200950\u2009copies\/mL at months 1, 7 and 13 was analysed using intention\u2010to\u2010treat (ITT) and on\u2010treatment (OT) approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CAB+RPV LA was administered to 35% of the hospital's cohort (151\/429). Of the 151 patients, 80% were male, with a median age of 40\u2009years. A total of 116 patients reached 13\u2009months of treatment. After a median follow\u2010up of 18.8\u2009months (interquartile range [IQR]: 11\u201323.7), 28 (18.5%) patients discontinued treatment, 3 (2%) of them due to VF (one with resistance mutations to both rilpivirine and cabotegravir). The proportions of patients with HIV\u2010RNA\u2009&lt;\u200950\u2009copies\/mL at months 1, 7 and 13 were 96%, 91% and 85% (ITT) and 96%, 95% and 93% (OT), respectively. Reasons for discontinuation included VF (2%), adverse events (4%), poor adherence (3%), transfer to another hospital (5%), oral bridging (4%) and difficulty attending appointments (1%). The modified therapeutic failure rate (excluding oral bridging and transfers) was 7.42 (95% confidence interval [CI]: 4.3\u201312.0) per 100 person\u2010years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAB+RPV LA appears to be an effective, safe and durable option for a switch strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70230","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:58:01Z","timestamp":1774515481000},"page":"1075-1083","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of long\u2010acting cabotegravir and rilpivirine in people living with\n                    <scp>HIV<\/scp>\n                    : A prospective observational cohort study"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0578-9214","authenticated-orcid":false,"given":"Ana","family":"Codonal","sequence":"first","affiliation":[{"name":"Pharmacy Department Hospital Santos Reyes  Aranda de Duero Spain"},{"name":"University of Alcal\u00e1  Alcal\u00e1 de Henares Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"L\u00e1zaro","sequence":"additional","affiliation":[{"name":"University of Alcal\u00e1  Alcal\u00e1 de Henares Spain"},{"name":"Pharmacy Department Hospital Universitario de Guadalajara  Guadalajara Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Internal Medicine Department Hospital Universitario de Guadalajara  Guadalajara Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Delgado","sequence":"additional","affiliation":[{"name":"Internal Medicine Department Hospital Universitario de Guadalajara  Guadalajara Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-7405","authenticated-orcid":false,"given":"Miguel","family":"Torralba","sequence":"additional","affiliation":[{"name":"University of Alcal\u00e1  Alcal\u00e1 de Henares Spain"},{"name":"Internal Medicine Department Hospital Universitario de Guadalajara  Guadalajara Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla\u2010La Mancha (IDISCAM)  Castilla\u2010La Mancha Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_8_3_1","unstructured":"European AIDS Clinical Society.Guidelines version 12.0. 2023. [cited 2024 Jul 10].\u00a0https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf"},{"key":"e_1_2_8_4_1","volume-title":"GESIDA\u2010SEIMC Guidelines on Antiretroviral Therapy in Adults with HIV Infection. January 2025 Update","author":"GESIDA\/SEIMC Expert Group","year":"2025"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.055"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211009011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010020\u201002918\u2010x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab324"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010023\u201000840\u2010y"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae016"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae326"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(23)00136\u20104"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004388"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003760"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23\u20100788"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.059"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1427"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad657"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1443"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(24)00289\u20105"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad370"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.107"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf389"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2023.0108"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimce.2022.09.007"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:08:27Z","timestamp":1783447707000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/hiv.70230"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70230","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}